- Home
- MNMD vs FISI Comparison
MNMD vs FISI Comparison
Compare MNMD & FISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNMD | FISI |
|---|---|---|
| Founded | 2019 | 1817 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 615.8M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | MNMD | FISI |
|---|---|---|
| Price | $12.61 | $32.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $25.78 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 1.5M | 105.8K |
| Earning Date | 11-06-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $116,735,000.00 |
| Revenue This Year | N/A | $124.17 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $20.97 |
| 52 Week High | $14.43 | $32.99 |
Technical Indicators
Market Signals| Indicator | MNMD | FISI |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 76.08 |
| Support Level | $12.19 | $30.83 |
| Resistance Level | $13.45 | $31.42 |
| Average True Range (ATR) | 0.70 | 0.58 |
| MACD | 0.08 | 0.19 |
| Stochastic Oscillator | 72.07 | 96.17 |
Price Performance
Historical ComparisonAbout MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.